Table 1 |
|||
|
Demographic features and symptom scores in fibromyalgia patients and controls. |
|||
|
Variable |
Fibromyalgia (n = 22) |
Control (n = 22) |
P value |
|
|
|||
|
Age (years) |
32.4 ± 7.9 |
30.4 ± 7.4 |
0.406 |
|
Body mass index (kg/m2) |
24.6 ± 4.4 |
25.0 ± 3.2 |
0.719 |
|
Disease duration (years) |
6.8 ± 6.1 |
N/A |
N/A |
|
Total FIQ score |
64.8 ± 14.1 |
12.0 ± 10.7 |
< 0.0001 |
|
VAS disability |
6.5 ± 2.3 |
0.5 ± 1.1 |
< 0.0001 |
|
VAS pain |
7.2 ± 2.2 |
0.7 ± 1.5 |
< 0.0001 |
|
VAS fatigue |
8.3 ± 1.4 |
1.8 ± 2.2 |
< 0.0001 |
|
VAS sleep |
7.3 ± 3.1 |
2.1 ± 2.4 |
< 0.0001 |
|
VAS morning stiffness |
7.2 ± 2.5 |
0.7 ± 1.4 |
< 0.0001 |
|
VAS anxiety |
7.3 ± 2.4 |
2.1 ± 2.3 |
< 0.0001 |
|
VAS depression |
6.3 ± 3.1 |
1.8 ± 2.5 |
< 0.0001 |
|
Total COMPASS score |
53.6 ± 18.2 |
13.5 ± 10.6 |
< 0.0001 |
|
Orthostatic intolerance |
20.4 ± 9.6 |
5.2 ± 5.8 |
< 0.0001 |
|
Vasomotor domain |
3.3 ± 2.9 |
0.4 ± 1.1 |
< 0.0001 |
|
Secretomotor |
4.7 ± 3.6 |
1.0 ± 1.5 |
< 0.0001 |
|
Gastroparesis |
2.9 ± 1.5 |
0.5 ± 0.7 |
< 0.0001 |
|
Diarrhea |
7.4 ± 5.4 |
2.5 ± 3.1 |
0.001 |
|
Constipation |
4.4 ± 2.4 |
1.1 ± 1.2 |
< 0.0001 |
|
Bladder |
4.0 ± 4.7 |
1.0 ± 1.6 |
0.010 |
|
Pupillomotor |
2.8 ± 1.2 |
0.7 ± 1.1 |
< 0.0001 |
|
Sleep |
2.8 ± 1.7 |
0.5 ± 0.8 |
< 0.0001 |
|
Syncope |
0.5 ± 1.4 |
0.1 ± 0.8 |
0.305 |
|
Understatement index |
0.8 ± 1.3 |
3.0 ± 2.9 |
0.003 |
|
Psychosomatic index |
1.2 ± 1.5 |
0.2 ± 0.6 |
0.004 |
|
MAF |
40.3 ± 5.5 |
15.6 ± 11.3 |
< 0.0001 |
|
MOS |
60.5 ± 11.2 |
19.2 ± 10.4 |
< 0.0001 |
|
SF-36 mental component |
38.9 ± 5.3 |
42.2 ± 5.2 |
0.043 |
|
SF-36 physical component |
53.0 ± 7.6 |
63.0 ± 83 |
< 0.0001 |
|
HADS depression |
7.3 ± 3.0 |
3.9 ± 4.4 |
0.005 |
|
HADS anxiety |
12.3 ± 4.0 |
5.5 ± 2.9 |
< 0.0001 |
|
|
|||
|
COMPASS, composite autonomic symptom scale; FIQ, fibromyalgia impact questionnaire; HADS, hospital anxiety and depression scale; MAF, multidimensional assessment of fatigue; MOS, medical outcome sleep scale; SF-36, short form 36 items health survey; VAS, visual analogue scale. N/A = not applicable. |
|||
|
Lerma et al. Arthritis Research & Therapy 2011 13:R185 doi:10.1186/ar3513 |
|||